Antiviral effect of human saliva against hantavirus

Journal of Medical Virology

Volumn 80, Issue 12, 2008, Pages 2122-2126

  Hardestam, Jonas ^a,b   Petterson, Lisa ^c   Ahlm, Clas ^c   Evander, Magnus ^c   Lundkvist, Åke ^a,b   Klingström, Jonas ^a,b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Antiviral effect; Hantavirus; HFRS; HPS; Innate immunity; Mucin; Saliva

Indexed keywords

HISTATIN 5; LACTOFERRIN; LYSOZYME; MUCIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; HANTAVIRUS; HUMAN; INOCULATION; NONHUMAN; SALIVA; SEROCONVERSION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTIVITY; VIRUS REPLICATION; VOLE;

ANIMALS; ANTIVIRAL AGENTS; ARVICOLINAE; HANTAVIRUS; HANTAVIRUS INFECTIONS; HISTATINS; HUMANS; LACTOFERRIN; MUCINS; MURAMIDASE; SALIVA; VIRUS REPLICATION;

CLETHRIONOMYS GLAREOLUS; HANTAVIRUS; PUUMALA VIRUS; RODENTIA;

EID: 57349177890     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21332     Document Type: Article

References (31)

1. Baron S, Poast J, Cloyd MW. 1999. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med 159:303-310.
2. Bergey EK, Gu M, Collins AR, Bradway SD, Levine MJ. 1993. Modulation of herpes simplex virus type 1 replication by human salivary secretions. Oral Microbiol Immunol 8:89-93.
3. Bergey EJ, Cho MI, Blumberg BM, Hammarskjöld ML, Rekosh D, Epstein LG, Levine MJ. 1994. Inhibition of HIV-1 with human salivary mucins. J Acquir Immune Defic Syndr 7:995-1002.
4. Bolscher JGM, Groenink J, van der Kwaak JS, van den Keijbus PAM, van't Hof W, Veerman ECI, Nieuw Amerongen AV. 1999. Detection and quantification of MUC7 in submandibular, sublingual, palatine and labial saliva by anti-peptide antiserum. J Dent Res 78:1362-1369.
5. Bolscher JG, Nazmi K, Ran LJ, van Engelenburg FA, Schuitemaker H, Veerman EC, Nieuw Amerongen AV. 2002. Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. Eur J Oral Sci 110:149-156.
6. Coppenhaver DD, Sriyuktasuth-Woo P, Baron S, Barr CE, Qureshi MN. 1994. Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. N Engl J Med 330:1314-1315.
7. Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J. 1998. Identification of a CD36-related thrombospondin-1 binding domain in HIV-1 envelope glycoprotein gp120: Relationship to HIV-1 specific inhibitory factors in human saliva. J Exp Med 187:25-35.
8. Evander M, Eriksson I, Pettersson L, Juto P, Ahlm C, Olsson GE, Bucht G, Allard A. 2007. Puumala hantavirus viremia diagnosed by real-time reverse transcriptase PCR using samples from patients with hemorrhagic fever and renal syndrome. J Clin Microbiol 45:2491-2497.
9. Faulkner GC, Krajewski AS, Crawford DH. 2000. The ins and outs of EBV infection. Trends Microbiol 8:185-189.
10. Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, Hjelle B, Delgado I, Lee SJ, Mertz GJ. 2007. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile. J Infect Dis 195:1563-1571.
11. Fox PC, Wolff A, Yeh C, Atkinson J, Baum BJ. 1988. Saliva inhibits HIV-1 infectivity. J Am Dent Assoc 116:635-637.
12. Groot F, Sanders RW, ter Brake O, Nazmi K, Veerman EC, Bolscher JG, Berkhout B. 2006. Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. J Virol 80:9236-9243.
13. Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U. 2003. Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defence against influenza A viruses. Am J Physiol Lung Cell Mol Physiol 285:L1066-L1076.
14. Hartshorn KL, Ligtenberg A, White MR, Van Eijk M, Hartshorn M, Pemberton L, Holmskov U, Crouch E. 2006. Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-influenza activities and interactions with surfactant protein D that vary according to donor source and sialylation. Biochem J 393:545-553.
15. Klingström J, Åkerström S, Hardestam J, Stoltz M, Simon M, Falk KI, Mirazimi A, Rottenberg M, Lundkvist Å. 2006. Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions. Eur J Immunol 36:2649-2657.
16. Lazaro ME, Cantoni GE, Calanni LM, Resa AJ, Herrero ER, Iacono MA, Enria DA, González Cappa SM. 2007. Clusters of hantavirus infection, southern Argentina. Emerg Infect Dis 13:104-110.
17. Lee-Huang S, Huang PL, Sun Y, Huang PL, Kung HF, Blithe DL, Chen HC. 1999. Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci USA 96:2678-2681.
18. Lundkvist Å, Cheng Y, Brus Sjölander K, Niklasson B, Vaheri A, Plyusnin A. 1997. Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNAs segment. J Virol 71:9515-9523.
19. Malamud D, Davis C, Berthold P, Roth E, Friedman H. 1993. Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses 9:633-637.
20. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula P. 2005. Person-to-person transmission of Andes virus. Emerg Infect Dis 11:1848-1853.
21. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. 1995. Secretory leukocyte protease inhibitor: A human salivary protein exhibiting anti-HIV-1 activity in vitro. J Clin Invest 96:456-464.
22. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. 1998. Human submandibular saliva inhibits HIV-1 infection by displacing gp120 from the virus. J Infect Dis 178:1635-1641.
23. Navarrete M, Pizarro E, Méndez C, Salazar P, Padula P, Zaror L, Otth C, Rodriquez E. 2007. Hantavirus ANDV distribution in human lungs and salivary glands. In: Abstracts of the VII international conference on HFRS, HPS and hantaviruses; Buenos Aires, Argentina; 2007 June 13-15; Abstract 103.
24. Padula P, Figueroa R, Navarrete M, Pizarro E, Cadiz R, Bellomo C, Jofre C, Zaror L, Rodriguez E, Murúa R. 2004. Transmission study of Andes hantavirus infection in wild sigmodontine rodents. J Virol 78:11972-11979.
25. Pettersson L, Klingström J, Hardestam J, Lundkvist A ° , Ahlm C, Evander M. 2008. Hantavirus RNA in saliva from patients with hemorrhagic fever with renal syndrome. Emerg Inf Dis 14:406-411.
26. Robinovitch MR, Ashley RL, Iverson JM, Vigoren EM, Oppenheim FG, Lamkin M. 2001. Parotid salivary basic proline rich proteins inhibit HIV-1 infectivity. Oral Dis 7:86-93.
27. Schmaljohn C, Hjelle B. 1997. Hantaviruses: A global disease problem. Emerg Infect Dis 3:95-104.
28. Shugars DC. 1999. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 179:S431-S435.
29. Shugars DC, Sweet SP, Malamud D, Kazmi SH, Page-Shafer K, Challacome SJ. 2002. Saliva and inhibition of HIV-1 infection: Molecular mechanisms. Oral Dis 8:169-175.
30. Van det Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK. 2001. Antiviral activities of lactoferrin. Antiviral Res 52:225-239.
31. Yanagihara R, Amyx HL, Gajdusek DC. 1985. Experimental infection with Puumala virus, the etiologic agent of nephropathia epidemica, in bank voles (Clethrionomys glareolus). J Virol 55:34-38.